PMID- 11511433
OWN - NLM
STAT- MEDLINE
DCOM- 20011018
LR  - 20190513
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 3
IP  - 4
DP  - 2001 Aug
TI  - Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a 
      substudy to the MERIT-HF trial.
PG  - 463-8
AB  - BACKGROUND: Beta-blockade usually causes a slight reduction in exercise capacity 
      among healthy subjects, while more variable results have been observed in chronic 
      heart failure (CHF), probably related to patients studied, methods and agent 
      used. The effect of metoprolol controlled release/extended release (CR/XL) on 
      peak oxygen uptake (peak VO(2)) in this patient population has not previously 
      been investigated. AIMS: We examined the effect of long-term treatment with the 
      selective beta(1)-receptor blocker metoprolol CR/XL once daily on exercise 
      capacity in patients with CHF. METHODS: Ninety-four patients (70 males and 24 
      females; mean age 63.6+/-10.6 years) with chronic symptomatic heart failure in 
      New York Heart Association (NYHA) functional class II-IV, and with ejection 
      fraction <or=40%, stabilized on optimum standard therapy were randomized to 
      metoprolol CR/XL or placebo in a double-blind trial. Exercise capacity was 
      evaluated by peak VO(2) at baseline, after 3 months and at the end of study (mean 
      follow-up 11.4+/-0.4 months). RESULTS: Compared with placebo metoprolol CR/XL 
      produced a significant decrease in heart rate by 11 beats/min at rest and 18 
      beats/min at peak exercise. There was a tendency for a temporal decline in peak 
      VO(2) after 3 months of therapy in both groups, but altogether peak VO(2) 
      remained unchanged from baseline with no difference between the groups at 1 year. 
      CONCLUSIONS: In patients with moderate to severe CHF, 11.4 months of 
      beta(1)-blockade with metoprolol CR/XL had no effect on exercise capacity when 
      compared with placebo or baseline.
FAU - Gullestad, L
AU  - Gullestad L
AD  - Department of Cardiology, Division of Heart and Lung Diseases, Rikshospitalet, 
      0027 Oslo, Norway. lagulles@online.no
FAU - Manhenke, C
AU  - Manhenke C
FAU - Aarsland, T
AU  - Aarsland T
FAU - Skardal, R
AU  - Skardal R
FAU - Fagertun, H
AU  - Fagertun H
FAU - Wikstrand, J
AU  - Wikstrand J
FAU - Kjekshus, J
AU  - Kjekshus J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Delayed-Action Preparations)
RN  - GEB06NHM23 (Metoprolol)
SB  - IM
MH  - Aged
MH  - Chronic Disease
MH  - Confidence Intervals
MH  - Delayed-Action Preparations
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Exercise Tolerance/*drug effects
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Heart Function Tests
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Long-Term Care
MH  - Male
MH  - Metoprolol/*administration & dosage
MH  - Middle Aged
MH  - Oxygen Consumption/physiology
MH  - Probability
MH  - Reference Values
MH  - Treatment Outcome
EDAT- 2001/08/21 10:00
MHDA- 2001/10/19 10:01
CRDT- 2001/08/21 10:00
PHST- 2001/08/21 10:00 [pubmed]
PHST- 2001/10/19 10:01 [medline]
PHST- 2001/08/21 10:00 [entrez]
AID - S1388-9842(01)00146-5 [pii]
AID - 10.1016/s1388-9842(01)00146-5 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2001 Aug;3(4):463-8. doi: 10.1016/s1388-9842(01)00146-5.